Drug class
CD19-directed Chimeric Antigen Receptor; Genetically-modified Autologous T Cells; CD19-specific Chimeric Antigen Receptor; Increased T Lymphocyte Activation
Mechanism of action
CD19 Receptor Interactions [MoA]
General use cases
- adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
